<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To examine the effects of <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> and repaglinide on <z:chebi fb="105" ids="17234">glucose</z:chebi> stimulated insulin release, incretins, <z:mp ids='MP_0003674'>oxidative stress</z:mp> and cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> suboptimally treated with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A randomized clinical trial was performed recruiting 27 subjects (HbA(1c) between 7.5 and 10.5%) free from cardiovascular and <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi>, insulin, C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1), <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="7" ids="16670">peptide</z:chebi> (GIP), total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status, F(2)-isoprostane, interleukin-6 and cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules were measured during an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> load at baseline and after eight weeks of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The areas under the curve were analysed at 45, 60 and 120 min (AUC(45), AUC(60), AUC(120)) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Significant improvements in <z:chebi fb="105" ids="17234">glucose</z:chebi> were observed with repaglinide (HBA(1c): -1.5%, fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>: -2.8 mmol/L, 2-h <z:chebi fb="105" ids="17234">glucose</z:chebi>: -3.7 mmol/L, AUC(120): -18.9%) and <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (-1.0%, -2.2 mmol/L, -2.5 mmol/L, -17.5%) </plain></SENT>
<SENT sid="5" pm="."><plain>Repaglinide was also associated with an increase in the AUC(60) and AUC(120) for insulin (+56%, +61%) and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (+41%, +36%) </plain></SENT>
<SENT sid="6" pm="."><plain>GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group </plain></SENT>
<SENT sid="7" pm="."><plain>No association was observed between GLP-1, GIP-1 and plasma markers of <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> release </plain></SENT>
<SENT sid="9" pm="."><plain>We observed no direct effects of <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> or repaglinide on plasma levels of GLP-1 or GIP </plain></SENT>
<SENT sid="10" pm="."><plain>We observed no associations of GLP-1 and GIP with plasma markers of <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
</text></document>